{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T04:59:40Z","timestamp":1785387580976,"version":"3.55.0"},"reference-count":51,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T00:00:00Z","timestamp":1785369600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>\n                      Wolfram syndrome is a rare autosomal recessive disorder caused by pathogenic variants in the\n                      <jats:italic>WFS1<\/jats:italic>\n                      gene and characterized by early-onset, insulin-dependent diabetes mellitus, optic atrophy, sensorineural hearing loss, arginine vasopressin deficiency, and progressive neurodegeneration driven by chronic endoplasmic reticulum (ER) stress; no proven disease-modifying therapy currently exists. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) augment glucose-dependent insulin secretion and, in preclinical models, preserve \u03b2-cell mass, attenuate ER stress, and confer neuroprotection \u2014 properties of particular therapeutic relevance to Wolfram syndrome.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a retrospective cohort study of 84 participants with genetically confirmed Wolfram syndrome and insulin-dependent diabetes mellitus enrolled in the Washington University Wolfram Syndrome International Registry and Clinical Study, with additional longitudinal data for participants co-enrolled in the Tracking Neurodegeneration in Early Wolfram Syndrome study. We characterized the prevalence of GLP-1 RA use and the documented rationale for initiation, and evaluated within-participant pre\u2013post changes in glycemic (HbA1c, body mass index) and visual (LogMAR best-corrected visual acuity, retinal nerve fiber layer thickness) parameters, along with adverse effects and reasons for discontinuation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Thirty of the 84 participants (35.7%) had received a GLP-1 RA in addition to insulin. No statistically significant changes in HbA1c or body mass index were observed at one or two years. Best-corrected visual acuity (LogMAR) declined significantly at two years, consistent with expected disease progression. Gastrointestinal adverse effects were common (56.7% of users) and were the leading cause of discontinuation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>In this largest reported evaluation of GLP-1 RA use in Wolfram syndrome, these agents were already integrated into clinical care and were generally tolerated, but showed no glycemic or visual benefit over one to two years. Given the retrospective, uncontrolled design, the small number of participants with paired pre\u2013post measurements, and the absence of a longitudinally followed comparator group, these findings are preliminary and hypothesis-generating rather than definitive, and provide a foundation for future prospective trials evaluating GLP-1 RAs as a potential disease-modifying strategy in Wolfram syndrome.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fendo.2026.1847818","type":"journal-article","created":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T04:21:13Z","timestamp":1785385273000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Evaluating the use of GLP-1 receptor agonists in Wolfram syndrome patients"],"prefix":"10.3389","volume":"17","author":[{"given":"Laura A.","family":"Lee","sequence":"first","affiliation":[{"name":"Department of Medicine, Division of Endocrinology, Metabolism, and Lipid Research, Washington University School of Medicine","place":["St. Louis, MO, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abby F.","family":"Tang","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Endocrinology, Metabolism, and Lipid Research, Washington University School of Medicine","place":["St. Louis, MO, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna E.","family":"Asako","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Endocrinology, Metabolism, and Lipid Research, Washington University School of Medicine","place":["St. Louis, MO, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah F.","family":"Ning","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Endocrinology, Metabolism, and Lipid Research, Washington University School of Medicine","place":["St. Louis, MO, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hayden A.","family":"Reed","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Endocrinology, Metabolism, and Lipid Research, Washington University School of Medicine","place":["St. Louis, MO, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleanor","family":"Duncan","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Endocrinology, Metabolism, and Lipid Research, Washington University School of Medicine","place":["St. Louis, MO, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather M.","family":"Lugar","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Washington University School of Medicine","place":["St. Louis, MO, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Hoekel","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology & Visual Sciences, Washington University School of Medicine","place":["St. Louis, MO, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bess A.","family":"Marshall","sequence":"additional","affiliation":[{"name":"Departments of Pediatrics and Cell Biology, Division of Endocrinology and Diabetes, Washington University School of Medicine","place":["St. Louis, MO, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamara","family":"Hershey","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Washington University School of Medicine","place":["St. Louis, MO, United States"]},{"name":"Department of Neurology, Washington University School of Medicine","place":["St. Louis, MO, United States"]},{"name":"Department of Radiology, Washington University School of Medicine","place":["St. Louis, MO, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumihiko","family":"Urano","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Endocrinology, Metabolism, and Lipid Research, Washington University School of Medicine","place":["St. Louis, MO, United States"]},{"name":"Department of Pathology and Immunology, Washington University School of Medicine","place":["St. Louis, MO, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,30]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1007\/s11892-015-0702-6","article-title":"Wolfram syndrome: Diagnosis, management, and treatment","volume":"16","author":"Urano","year":"2016","journal-title":"Curr Diabetes Rep"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1177\/26330040211039518","article-title":"Wolfram syndrome: New pathophysiological insights and therapeutic strategies","volume":"2","author":"Mishra","year":"2021","journal-title":"Ther Adv Rare Dis"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1198171","DOI":"10.1101\/2023.02.15.23284904","article-title":"Genotype and clinical characteristics of patients with Wolfram syndrome and WFS1-related disorders","volume":"14","author":"Lee","year":"2023","journal-title":"Front Genet"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1038\/2441","article-title":"A gene encoding a transmembrane protein is mutated in patients with diabetes mellitus and optic atrophy (Wolfram syndrome)","volume":"20","author":"Inoue","year":"1998","journal-title":"Nat Genet"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.m507426200","article-title":"WFS1 is a novel component of the unfolded protein response and maintains homeostasis of the endoplasmic reticulum in pancreatic {beta}-cells","volume":"280","author":"Fonseca","year":"2005","journal-title":"J Biol Chem"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1172\/jci39678","article-title":"Wolfram syndrome 1 gene negatively regulates ER stress signaling in rodent and human cells","volume":"120","author":"Fonseca","year":"2010","journal-title":"J Clin Invest"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1421055111","article-title":"A calcium-dependent protease as a potential therapeutic target for Wolfram syndrome","volume":"111","author":"Lu","year":"2014","journal-title":"Proc Natl Acad Sci USA"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(95)92473-6","article-title":"Neurodegeneration and diabetes: UK nationwide study of Wolfram (DIDMOAD) syndrome","volume":"346","author":"Barrett","year":"1995","journal-title":"Lancet"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0040604","article-title":"Early brain vulnerability in Wolfram syndrome","volume":"7","author":"Hershey","year":"2012","journal-title":"PloS One"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.64898\/2026.07.02.26357130","article-title":"Consensus recommendations for the clinical management of Wolfram syndrome using a Delphi method","author":"Elliott","year":"2026","journal-title":"medRxiv"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2026.1839135","article-title":"Genotype-based severity scoring system in Wolfram syndrome: Correlation with onset of cardinal symptoms and WFS1 gene variant types","author":"Oiknine","year":"2026","journal-title":"medRxiv"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1111\/pedi.13291","article-title":"Longitudinal progression of diabetes mellitus in Wolfram syndrome: The Washington University Wolfram Research Clinic experience","volume":"23","author":"Ray","year":"2022","journal-title":"Pediatr Diabetes"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2022.07.003","article-title":"Longitudinal changes in vision and retinal morphology in Wolfram syndrome","volume":"243","author":"O'bryhim","year":"2022","journal-title":"Am J Ophthalmol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1838257","DOI":"10.64898\/2026.03.22.713521","article-title":"Synaptic alterations are preceding the axonal loss in optic atrophy of Wolfram syndrome mouse model","volume":"20","author":"Gurram","year":"2026","journal-title":"Front Neurosci"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1097\/wno.0000000000002451","article-title":"Optic atrophy in Wolfram syndrome type 1: A retrospective analysis of visual outcomes and biomarker correlates","author":"Mcneely","year":"2026","journal-title":"J Neuroophthalmol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.18.12.1566","article-title":"Morbidity and mortality in the Wolfram syndrome","volume":"18","author":"Kinsley","year":"1995","journal-title":"Diabetes Care"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.tips.2019.07.011","article-title":"Current landscape of treatments for Wolfram syndrome","volume":"40","author":"Abreu","year":"2019","journal-title":"Trends Pharmacol Sci"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.145188","article-title":"A phase Ib\/IIa clinical trial of dantrolene sodium in patients with Wolfram syndrome","volume":"6","author":"Abreu","year":"2021","journal-title":"JCI Insight"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.156549","article-title":"Multidimensional analysis and therapeutic development using patient iPSC-derived disease models of Wolfram syndrome","volume":"7","author":"Kitamura","year":"2022","journal-title":"JCI Insight"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1172\/jci198519","article-title":"Phase II trial of sodium phenylbutyrate and taurursodiol in Wolfram syndrome","volume":"136","author":"Urano","year":"2026","journal-title":"J Clin Invest"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-025-01183-8","article-title":"GLP-1-based therapies for diabetes, obesity and beyond","volume":"24","author":"Drucker","year":"2025","journal-title":"Nat Rev Drug Discov"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1056\/nejmcibr2409089","article-title":"Discovery of GLP-1-based drugs for the treatment of obesity","volume":"392","author":"Drucker","year":"2025","journal-title":"N Engl J Med"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2025.103363","article-title":"The expanding role of GLP-1 receptor agonists: A narrative review of current evidence and future directions","volume":"86","author":"Moiz","year":"2025","journal-title":"EClinicalMedicine"},{"key":"B24","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/s41591-025-04124-5","article-title":"The expanding landscape of GLP-1 medicines","volume":"32","author":"Drucker","year":"2026","journal-title":"Nat Med"},{"key":"B25","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1016\/s0140-6736(25)02105-1","article-title":"Glucagon-like receptor agonists and next-generation incretin-based medications: Metabolic, cardiovascular, and renal benefits","volume":"407","author":"Nauck","year":"2026","journal-title":"Lancet"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.2147\/dddt.s348055","article-title":"The role of glucagon-like peptide-1 receptor agonists (GLP-1 RA) in diabetes-related neurodegenerative diseases","volume":"16","author":"Cheng","year":"2022","journal-title":"Drug Des Devel Ther"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2022.106550","article-title":"Glucagon-like peptide-1 (GLP-1) receptor agonists and neuroinflammation: Implications for neurodegenerative disease treatment","volume":"186","author":"Kopp","year":"2022","journal-title":"Pharmacol Res"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2024.09.003","article-title":"GLP-1 programs the neurovascular landscape","volume":"36","author":"Chen","year":"2024","journal-title":"Cell Metab"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2025.1675552","article-title":"GLP-1 receptor agonists: Exploration of transformation from metabolic regulation to multi-organ therapy","volume":"16","author":"Gong","year":"2025","journal-title":"Front Pharmacol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-018-4679-y","article-title":"Activation of GLP-1 receptor signalling alleviates cellular stresses and improves beta cell function in a mouse model of Wolfram syndrome","volume":"61","author":"Kondo","year":"2018","journal-title":"Diabetologia"},{"key":"B31","doi-asserted-by":"publisher","first-page":"10220","DOI":"10.1038\/s41598-017-09392-x","article-title":"Wfs1-deficient rats develop primary symptoms of Wolfram syndrome: Insulin-dependent diabetes, optic nerve atrophy and medullary degeneration","volume":"7","author":"Plaas","year":"2017","journal-title":"Sci Rep"},{"key":"B32","doi-asserted-by":"publisher","first-page":"10183","DOI":"10.1038\/s41598-018-28314-z","article-title":"Preventive treatment with liraglutide protects against development of glucose intolerance in a rat model of Wolfram syndrome","volume":"8","author":"Toots","year":"2018","journal-title":"Sci Rep"},{"key":"B33","doi-asserted-by":"publisher","first-page":"15742","DOI":"10.1038\/s41598-019-52295-2","article-title":"GLP-1 receptor agonist liraglutide has a neuroprotective effect on an aged rat model of Wolfram syndrome","volume":"9","author":"Seppa","year":"2019","journal-title":"Sci Rep"},{"key":"B34","doi-asserted-by":"publisher","first-page":"3193","DOI":"10.3390\/cells10113193","article-title":"Early intervention and lifelong treatment with GLP1 receptor agonist liraglutide in a Wolfram syndrome rat model with an emphasis on visual neurodegeneration, sensorineural hearing loss and diabetic phenotype","volume":"10","author":"Jagomae","year":"2021","journal-title":"Cells"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-023-05905-8","article-title":"GLP-1R agonists demonstrate potential to treat Wolfram syndrome in human preclinical models","volume":"66","author":"Gorgogietas","year":"2023","journal-title":"Diabetologia"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2021.755365","article-title":"Case report: Off-label liraglutide use in children with Wolfram syndrome type 1: Extensive characterization of four patients","volume":"9","author":"Frontino","year":"2021","journal-title":"Front Pediatr"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.3389\/fcdhc.2023.1171091","article-title":"GLP-1 receptor agonists as promising disease-modifying agents in WFS1 spectrum disorder","volume":"4","author":"Panfili","year":"2023","journal-title":"Front Clin Diabetes Healthc"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.2337\/dc26-s006","article-title":"6. Glycemic goals, hypoglycemia, and hyperglycemic crises: Standards of care in diabetes-2026","volume":"49","author":"American Diabetes Association Professional Practice Committee For","year":"2026","journal-title":"Diabetes Care"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2018.03.001","article-title":"Mechanisms of action and therapeutic application of glucagon-like peptide-1","volume":"27","author":"Drucker","year":"2018","journal-title":"Cell Metab"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmet.2020.101102","article-title":"GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art","volume":"46","author":"Nauck","year":"2021","journal-title":"Mol Metab"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.2337\/db13-0717","article-title":"\u03b2-cell dysfunction due to increased ER stress in a stem cell model of Wolfram syndrome","volume":"63","author":"Shang","year":"2014","journal-title":"Diabetes"},{"key":"B42","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1056\/nejmoa2032183","article-title":"Once-weekly semaglutide in adults with overweight or obesity","volume":"384","author":"Wilding","year":"2021","journal-title":"N Engl J Med"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaapos.2014.07.162","article-title":"Ophthalmologic correlates of disease severity in children and adolescents with Wolfram syndrome","volume":"18","author":"Hoekel","year":"2014","journal-title":"J AAPOS"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1136\/bmjophth-2017-000081","article-title":"Visual pathway function and structure in Wolfram syndrome: Patient age, variation and progression","volume":"3","author":"Hoekel","year":"2018","journal-title":"BMJ Open Ophthalmol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2014-305745","article-title":"Retinal nerve fibre layer thickness floor and corresponding functional loss in glaucoma","volume":"99","author":"Mwanza","year":"2015","journal-title":"Br J Ophthalmol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.11-8644","article-title":"Retinal nerve fiber layer thickness reproducibility using seven different OCT instruments","volume":"53","author":"Pierro","year":"2012","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/694613","article-title":"Prospective study on retinal nerve fibre layer thickness changes in isolated unilateral retrobulbar optic neuritis","volume":"2013","author":"Yau","year":"2013","journal-title":"Sci World J"},{"key":"B48","doi-asserted-by":"publisher","first-page":"145","DOI":"10.3390\/jcm12010145","article-title":"Clinical recommendations to manage gastrointestinal adverse events in patients treated with GLP-1 receptor agonists: A multidisciplinary expert consensus","volume":"12","author":"Gorgojo-Martinez","year":"2022","journal-title":"J Clin Med"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.57349","article-title":"Discontinuation and reinitiation of dual-labeled GLP-1 receptor agonists among US adults with overweight or obesity","volume":"8","author":"Rodriguez","year":"2025","journal-title":"JAMA Netw Open"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1172\/jci194740","article-title":"The science of safety: Adverse effects of GLP-1 receptor agonists as glucose-lowering and obesity medications","volume":"136","author":"Jalleh","year":"2026","journal-title":"J Clin Invest"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(03)14571-0","article-title":"Genetic cause of hyperglycaemia and response to treatment in diabetes","volume":"362","author":"Pearson","year":"2003","journal-title":"Lancet"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1847818\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T04:21:13Z","timestamp":1785385273000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1847818\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,30]]},"references-count":51,"alternative-id":["10.3389\/fendo.2026.1847818"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2026.1847818","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,30]]},"article-number":"1847818"}}